MCID: MNC006
MIFTS: 49

Monoclonal Gammopathy of Uncertain Significance

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Monoclonal Gammopathy of Uncertain Significance

MalaCards integrated aliases for Monoclonal Gammopathy of Uncertain Significance:

Name: Monoclonal Gammopathy of Uncertain Significance 12 14
Monoclonal Gammopathy of Undetermined Significance 12 72 49 69
Mgus 12 49

Classifications:



External Ids:

Disease Ontology 12 DOID:7442
ICD10 32 D47.2
UMLS 69 C0026470

Summaries for Monoclonal Gammopathy of Uncertain Significance

NIH Rare Diseases : 49 Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop. Those with stable levels of monoclonal protein typically do not require treatment. Last updated: 12/27/2016

MalaCards based summary : Monoclonal Gammopathy of Uncertain Significance, also known as monoclonal gammopathy of undetermined significance, is related to purpura and myeloma, multiple. An important gene associated with Monoclonal Gammopathy of Uncertain Significance is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Liraglutide and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are cellular and cardiovascular system

Wikipedia : 72 Monoclonal gammopathy of undetermined significance (MGUS, unknown or uncertain may be substituted for... more...

Related Diseases for Monoclonal Gammopathy of Uncertain Significance

Diseases related to Monoclonal Gammopathy of Uncertain Significance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
# Related Disease Score Top Affiliating Genes
1 purpura 30.3 CD40LG CD79A TNF
2 myeloma, multiple 26.9 B2M CD19 CD38 CD40LG CD79A IL6
3 scorpion envenomation 10.6 IL6 TNF
4 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 IL6 TNF
5 critical limb ischemia 10.6 IL6 TNF
6 retinitis pigmentosa 55 10.5 IL6 TNF
7 trench fever 10.5 CD40LG TNF
8 selective igg deficiency disease 10.5 CD40LG CD79A
9 c1q nephropathy 10.5 CD40LG CD79A
10 rheumatoid lung disease 10.5 CD40LG TNF
11 meningovascular neurosyphilis 10.5 CD40LG CD79A
12 alpha chain disease 10.5 CD40LG CD79A
13 brill-zinsser disease 10.5 CD40LG CD79A
14 exudative glomerulonephritis 10.5 CD40LG CD79A
15 cork-handlers' disease 10.5 CD40LG CD79A
16 salpingo-oophoritis 10.5 CD40LG CD79A
17 glossitis 10.5 IL6 TNF
18 early yaws 10.5 CD40LG CD79A
19 ventilation pneumonitis 10.5 CD40LG CD79A
20 laryngitis 10.5 IL6 TNF
21 chronic interstitial cystitis 10.5 CD40LG CD79A
22 axillary adenitis 10.5 CD40LG CD79A
23 cryofibrinogenemia 10.5 CD40LG CD79A
24 trichostrongyloidiasis 10.5 CD40LG CD79A
25 subacute bacterial endocarditis 10.5 CD40LG CD79A
26 heterophyiasis 10.5 CD40LG CD79A
27 immunoglobulin g deficiency 10.5 CD40LG CD79A
28 orbital granuloma 10.5 CD40LG CD79A
29 hyperglobulinemic purpura 10.4 CD40LG CD79A
30 gastroduodenitis 10.4 CD40LG CD79A
31 bacterial conjunctivitis 10.4 CD40LG CD79A
32 indolent myeloma 10.4 B2M MYOM2
33 heavy chain disease 10.4 CD40LG CD79A
34 ophthalmia neonatorum 10.4 CD40LG CD79A
35 parotid disease 10.4 CD40LG CD79A
36 farmer's lung 10.4 CD79A TNF
37 cerebral arteritis 10.4 CD40LG CD79A
38 mucocutaneous leishmaniasis 10.4 LTA TNF
39 selective immunoglobulin deficiency disease 10.4 CD40LG CD79A
40 extramedullary plasmacytoma 10.4 B2M IL6
41 geniculate herpes zoster 10.4 CD40LG CD79A
42 idiopathic achalasia 10.4 LTA TNF
43 smoldering myeloma 10.4 CD79A MYOM2
44 null-cell leukemia 10.4 IL6 LTA TNF
45 mononeuritis multiplex 10.4 CD40LG MAG
46 erythema elevatum diutinum 10.4 CD40LG CD79A
47 sporotrichosis 10.4 CD40LG CD79A
48 fallopian tube disease 10.4 CD40LG CD79A
49 hyperimmunoglobulin syndrome 10.4 CD40LG CD79A
50 acute respiratory distress syndrome 10.4 IL6 LTA TNF

Graphical network of the top 20 diseases related to Monoclonal Gammopathy of Uncertain Significance:



Diseases related to Monoclonal Gammopathy of Uncertain Significance

Symptoms & Phenotypes for Monoclonal Gammopathy of Uncertain Significance

MGI Mouse Phenotypes related to Monoclonal Gammopathy of Uncertain Significance:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 CD79A B2M NCAM1 IL6 CD19 TNF
2 cardiovascular system MP:0005385 10.03 B2M NSD2 IL6 CD19 TNF LTA
3 hematopoietic system MP:0005397 9.97 CD79A B2M MAG IL6 CD19 TNF
4 homeostasis/metabolism MP:0005376 9.96 CD79A B2M MAG IL6 CD19 TNF
5 endocrine/exocrine gland MP:0005379 9.91 B2M IL6 TNF LTA CD38 MAFB
6 immune system MP:0005387 9.85 B2M IL6 CD19 TNF LTA CD38
7 liver/biliary system MP:0005370 9.43 CD79A B2M IL6 CD19 TNF LTA
8 nervous system MP:0003631 9.32 B2M IL6 NCAM1 CD19 TNF LTA

Drugs & Therapeutics for Monoclonal Gammopathy of Uncertain Significance

Drugs for Monoclonal Gammopathy of Uncertain Significance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 230)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2 44147092
2 Hormone Antagonists Phase 4,Phase 2,Phase 1
3 Hormones Phase 4,Phase 3,Phase 2,Phase 1
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
5 Immunoglobulins Phase 4,Phase 2,Phase 1
6 Antibodies Phase 4,Phase 2,Phase 1
7 glucagon Phase 4
8 Glucagon-Like Peptide 1 Phase 4
9 Hypoglycemic Agents Phase 4
10 Incretins Phase 4
11
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
12
Iron Approved Phase 3 7439-89-6 23925
13
Morphine Approved, Investigational Phase 3 57-27-2 5288826
14
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
15
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
16
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
17
Ondansetron Approved Phase 3 99614-02-5 4595
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
20
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
21
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
22
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
23
Dalteparin Approved Phase 3 9005-49-6
24
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
25
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
28 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
30 Antiemetics Phase 3,Phase 2,Phase 1
31 Anti-Infective Agents Phase 3,Phase 2,Phase 1
32 Autonomic Agents Phase 3,Phase 2,Phase 1
33 Antirheumatic Agents Phase 3,Phase 2,Phase 1
34 ferric gluconate Phase 3
35 calcium heparin Phase 3
36
Serotonin Phase 3 50-67-9 5202
37 Analgesics Phase 3,Phase 2
38 Ferric Compounds Phase 3
39 Respiratory System Agents Phase 3
40 Fibrinolytic Agents Phase 3
41 Central Nervous System Depressants Phase 3
42 Adjuvants, Anesthesia Phase 3
43 Serotonin Agents Phase 3
44 Serotonin Antagonists Phase 3
45 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
46 Narcotics Phase 3
47 Neurotransmitter Agents Phase 3,Phase 2
48 Tranquilizing Agents Phase 3
49 Hematinics Phase 3,Phase 2
50 Heparin, Low-Molecular-Weight Phase 3

Interventional clinical trials:

(show top 50) (show all 96)

# Name Status NCT ID Phase Drugs
1 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
2 RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
3 Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Completed NCT01210716 Phase 3
4 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
5 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
6 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
7 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
8 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
9 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
10 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
12 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
13 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
14 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
15 The Treatment of Lenalidomide in Patients With POEMS Syndrome Unknown status NCT00971685 Phase 2 Lenalidomide and dexamethasone
16 Beta Alethine in Treating Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
17 The Efficacy and Safety of ITF2357 in AIS Unknown status NCT00442182 Phase 2 ITF2357
18 Imaging in MGUS, SMM and MM Completed NCT01237054 Phase 2 18-NaF PET;18-FDG PET/CT
19 Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Completed NCT00099047 Phase 2 celecoxib;placebo
20 Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma Completed NCT00006219 Phase 2 clarithromycin;prasterone
21 Ilaris (Canakinumab) in the Schnitzler Syndrome Completed NCT01245127 Phase 2 Ilaris
22 Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias Completed NCT02041325 Phase 2 Lenalidomide;Placebo
23 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
24 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
25 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
26 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
27 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
28 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
29 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
30 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
31 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
32 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
33 A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma Completed NCT01063907 Phase 1, Phase 2 KW-2478;Bortezomib
34 Efficacy and Safety of Canakinumab in Schnitzler Syndrome Completed NCT01276522 Phase 2 Canakinumab
35 Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) Completed NCT01045772 Phase 2 rilonacept
36 Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Recruiting NCT03236428 Phase 2 Daratumumab
37 Daratumumab in Treatment of PGNMID and C3 GN Recruiting NCT03095118 Phase 2 Daratumumab
38 Tocilizumab in Patients With Schnitzler's Syndrome Recruiting NCT03046381 Phase 2 Tocilizumab
39 Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Recruiting NCT02921893 Phase 2 Dexamethasone;Ixazomib Citrate;Lenalidomide
40 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Active, not recruiting NCT02566265 Phase 2
41 Ilaris® Effects in Schnitzler Syndrome (ILESCH) Active, not recruiting NCT01390350 Phase 2 Canakinumab;Placebo
42 Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance Suspended NCT00665652 Phase 2 Lenalidomide
43 Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance Terminated NCT00588822 Phase 2
44 Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Terminated NCT00942422 Phase 2
45 Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) Terminated NCT00899353 Phase 2
46 Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma Terminated NCT00538824 Phase 2 dexamethasone;thalidomide;lenalidomide
47 Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment Terminated NCT01548573 Phase 2 Dexamethasone;Cisplatin;Doxorubicin;Cyclophosphamide;Etoposide;Bortezomib;Thalidomide;Melphalan
48 Imaging Studies and the Development of Multiple Myeloma Withdrawn NCT01571726 Phase 2 Fluciclatide
49 Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer Unknown status NCT00004036 Phase 1 amifostine trihydrate;carboplatin;cyclophosphamide
50 A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1

Search NIH Clinical Center for Monoclonal Gammopathy of Uncertain Significance

Genetic Tests for Monoclonal Gammopathy of Uncertain Significance

Anatomical Context for Monoclonal Gammopathy of Uncertain Significance

MalaCards organs/tissues related to Monoclonal Gammopathy of Uncertain Significance:

38
Bone, Bone Marrow, B Cells, Testes, Liver, Heart, Prostate

Publications for Monoclonal Gammopathy of Uncertain Significance

Articles related to Monoclonal Gammopathy of Uncertain Significance:

(show all 15)
# Title Authors Year
1
The Immunotyping Distribution of Serum Monoclonal Paraprotein and Environmental Impact on Multiple Myeloma (MM) and Monoclonal Gammopathy of Uncertain Significance (MGUS) in Taiwan: A Medical Center-Based Experience. ( 26838245 )
2016
2
Nodular mucinosis associated with light-chain monoclonal gammopathy of uncertain significance. ( 27979308 )
2016
3
CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance. ( 26303094 )
2016
4
Autoantibodies against U1RNP and monoclonal gammopathy of uncertain significance: an unusual association. ( 19772812 )
2009
5
Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. ( 17535272 )
2007
6
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. ( 17576818 )
2007
7
Paraovarian hemangioma with immunoglobulin deposits in a patient with monoclonal gammopathy of uncertain significance and osteolytic lesions. ( 15455229 )
2005
8
Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. ( 15049904 )
2004
9
Prevalence of hepatitis C virus infection in IgM-type monoclonal gammopathy of uncertain significance and WaldenstrAPm macroglobulinemia. ( 15551289 )
2004
10
Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review. ( 11858359 )
2002
11
Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma. ( 11167813 )
2001
12
Late blood pool images after Tc-99m tetrofosmin injection in a patient with monoclonal gammopathy of uncertain significance and immunologic disorders. ( 10885696 )
2000
13
Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. ( 9763553 )
1998
14
Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. ( 8853167 )
1996
15
Erosive arthritis in monoclonal gammopathy of uncertain significance: report of four cases. ( 1747145 )
1991

Variations for Monoclonal Gammopathy of Uncertain Significance

Copy number variations for Monoclonal Gammopathy of Uncertain Significance from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13350 1 1 125000000 Gain Monoclonal gammopathy of undetermined significance
2 16482 1 125000000 249250621 Gain Monoclonal gammopathy of undetermined significance
3 55476 11 53700000 135006516 Gain Monoclonal gammopathy of undetermined significance
4 76533 13 32200000 40100000 Deletion NBEA Monoclonal gammopathy of undetermined significance
5 82835 14 17600000 107349540 Loss Monoclonal gammopathy of undetermined significance
6 89754 15 19000000 102531392 Gain Monoclonal gammopathy of undetermined significance
7 124088 19 1 26500000 Gain Monoclonal gammopathy of undetermined significance
8 166137 3 1 91000000 Gain Monoclonal gammopathy of undetermined significance
9 214491 6 61000000 171115067 Loss Monoclonal gammopathy of undetermined significance
10 253951 9 49000000 141213431 Gain Monoclonal gammopathy of undetermined significance

Expression for Monoclonal Gammopathy of Uncertain Significance

Search GEO for disease gene expression data for Monoclonal Gammopathy of Uncertain Significance.

Pathways for Monoclonal Gammopathy of Uncertain Significance

Pathways related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.16 B2M CD40LG IL6 LTA NCAM1 TNF
2
Show member pathways
12.63 B2M CD40LG IL6 LTA TNF
3
Show member pathways
12.53 CD40LG IL6 LTA TNF
4 12.01 B2M CD19 CD38 CD40LG CD79A NCAM1
5
Show member pathways
11.98 IL6 LTA TNF
6 11.95 CD40LG MAG NCAM1
7 11.91 B2M CD19 CD40LG
8 11.84 IL6 MAG TNF
9 11.78 IL6 LTA TNF
10
Show member pathways
11.75 IL6 LTA TNF
11 11.7 CD40LG LTA TNF
12 11.66 CD19 CD38 IL6 TNF
13
Show member pathways
11.63 CD40LG LTA TNF
14 11.6 LTA NCAM1 TNF
15 11.6 CD19 CD79A IL6 NCAM1
16
Show member pathways
11.49 CD40LG IL6 TNF
17 11.42 CD19 CD38 IL6 NCAM1 TNF
18 11.38 CD19 CD38 CD40LG
19 11.38 CD40LG IL6 LTA TNF
20 11.3 CD40LG IL6 TNF
21 11.16 CD19 CD38 CD79A IL6 NCAM1 TNF
22 11.15 CD19 CD40LG CD79A
23 10.99 CD40LG IL6 LTA TNF
24 10.97 IL6 TNF
25 10.88 IL6 TNF

GO Terms for Monoclonal Gammopathy of Uncertain Significance

Cellular components related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 B2M CD38 CD40LG NCAM1 TNF
2 external side of plasma membrane GO:0009897 9.1 B2M CD19 CD40LG CD79A NCAM1 TNF

Biological processes related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.7 CD40LG IL6 TNF
2 tumor necrosis factor-mediated signaling pathway GO:0033209 9.67 CD40LG LTA TNF
3 immune response GO:0006955 9.65 B2M CD40LG IL6 LTA TNF
4 defense response to Gram-positive bacterium GO:0050830 9.61 IL6 LTA TNF
5 B cell receptor signaling pathway GO:0050853 9.58 CD19 CD38 CD79A
6 positive regulation of chemokine production GO:0032722 9.51 IL6 TNF
7 humoral immune response GO:0006959 9.5 IL6 LTA TNF
8 negative regulation of growth of symbiont in host GO:0044130 9.48 LTA TNF
9 negative regulation of bone resorption GO:0045779 9.46 CD38 IL6
10 negative regulation of lipid storage GO:0010888 9.37 IL6 TNF
11 regulation of immunoglobulin secretion GO:0051023 9.16 CD40LG TNF
12 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 8.96 LTA TNF
13 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 8.62 LTA TNF

Molecular functions related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CD40LG IL6 LTA TNF
2 tumor necrosis factor receptor binding GO:0005164 8.8 CD40LG LTA TNF

Sources for Monoclonal Gammopathy of Uncertain Significance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....